You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company's nucleic acid extraction kits have offered labs relief from COVID-19-related shortages of traditional silica-based bind-wash-elute assays.
The company will issue units representing an aggregate of shares of common stock and warrants to purchase stock shares at an aggregate purchase price of $5.72.
The company, which recently raised $6 million in seed funding, is using single-cell proteomic analysis to identify markers of response in cancer immunotherapy.
The financing round brings the total amount of funding for Micronoma, a developer of microbiome-based cancer detection technology, to $6.5 million.
The company said it plans to use the funds to build out its annotated immune cell atlas and to expand its functional genomics capabilities.
Four genomics startups will join Illumina's Bay Area program, while five will join the Cambridge, UK program.
The Swedish firm will use the proceeds from the private placement to finance its global marketing and sales expansion.
The firm plans to use the net proceeds for general corporate purposes, including working capital and capital expenditures.
The San Diego-based company said it plans to use the funds to speed development of its ProteoCode proteomics platform.
The Seattle-based University of Washington spinout is planning to scale up the commercial roll-out of its single-cell, whole-transcriptome assay kit.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.
According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.
CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.
In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.